MarginsXMarginsX
Home › Markets › INTI

Inhibitor Therapeutics, Inc. (INTI)

INTI is quoted over the counter, not listed on an exchange. Inhibitor Therapeutics, Inc. files reports with the SEC; the numbers below come from SEC filings and from daily closes, each with its source.

Last trade · November 10, 2026
$0.0800
No trades since Nov 10, 2026; later closes repeat the last quote
1-year return
+60.0%
Market cap
$13.9M
Nano cap. From the Nov 10, 2026 last trade × 173.8M shares (10-Q cover page, Aug 14, 2026)
P/E and P/S
Net loss over the period · No revenue line filed
On trailing twelve months to June 30, 2026 (10-Q)

Closes: Yahoo Finance daily closes, last bar 2026-11-13.

Profile

FieldValue
TickerINTI, quoted over the counter
SEC CIK0001042418
OTC Markets tierOTCQB (price source, 2026-11-13)
SEC industry codePharmaceutical Preparations
Business addressTampa, FL
Incorporated inDE

Warning signs

Cash runway
1.9 months
$516K cash at June 30, 2026
Share count, 1 year
+0.7%
2025-08-13 to 2026-08-14 · +1.0% over 3 years
Going-concern doubt
Yes
10-Q filed August 14, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"These conditions and events raise substantial doubt about the Company's ability to continue as a going concern."
10-Q 2026-08-14
Cash and burn$516K cash; operating cash flow -$806K a quarter.Report 2026-06-30
Shares outstanding173,791,968 (2026-08-14); 172,573,545 a year earlier; 171,998,545 three years earlier.Cover page 2026-08-14
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorCherry Bekaert LLP, Tampa, Florida, United StatesPCAOB Form AP 2026-03-26
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2026
2026-06-30
Not filed-$614K-$775K$516K$48KNeeds four quarters10-Q 2026-08-14
Q1 2026
2026-03-31
Not filed-$686K-$1.1M$1.3M$58KNeeds four quarters10-Q 2026-08-14
Q4 2025
2025-12-31
Not filed-$1.3M-$601K$2.4M$62KNeeds four quarters10-K 2026-03-26
Q3 2025
2025-09-30
Not filed-$712K-$761K$3.0M$72KNeeds four quarters10-Q 2025-11-13
Q2 2025
2025-06-30
Not filed-$660K-$584K$3.7M$78KNeeds four quarters10-Q 2026-08-14
Q1 2025
2025-03-31
Not filed-$633K-$1.3M$4.3M$84KNeeds four quarters10-Q 2026-08-14
Q4 2024
2024-12-31
Not filed-$1.4M-$771K$5.6MNo debt tagsNeeds four quarters10-K 2026-03-26
Q3 2024
2024-09-30
Not filed-$731K-$720K$6.4MNo debt tagsNeeds four quarters10-Q 2025-11-13

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentPOS AM2019-04-26
Latest annual report10-K2026-03-26
Latest quarterly / interim10-Q2026-11-16
Latest current report8-K2026-09-18
Latest proxyDEF 14A2026-08-17

Source: SEC EDGAR submissions feed, 725 recent filings. All filings on EDGAR.

The full dossier has every filing, quarterly and annual financials, the health record and a price chart.

Open the full dossier